Matteo Tanzi, Enrica Montini, Agnese Rumolo, Antonia Moretta, Patrizia Comoli, Gloria Acquafredda, Jessica Rotella, Gloria Taurino, Francesca Compagno, Francesco Delle Cave, Cesare Perotti, Gian Luigi Marseglia, Marco Zecca, Daniela Montagna
BACKGROUND AIMS: Somatic cell therapy based on the infusion of donor-derived cytotoxic T lymphocytes (CTL) able to recognize patients' leukemia blasts (LB) is a promising approach to control leukemia relapse after allogeneic HSCT. The success of this approach strongly depends on the ex vivo generation of high-quality donor-derived anti-leukemia CTL in compliance with Good Manufacturing Practices (GMP). We previously described a procedure for generating large numbers of donor-derived anti-leukemia CTL through stimulation of CD8-enriched lymphocytes with dendritic cells (DCs) pulsed with apoptotic LB in the presence of interleukin (IL)-12, IL-7 and IL-15...
April 20, 2024: Cytotherapy